Academic Journal
Q1The Lancet HIV
About The Lancet HIV
About The Lancet HIV
The Lancet HIV is a peer-reviewed scholarly journal published by Elsevier Ltd (United Kingdom). It focuses on Immunology and Microbiology; Medicine.
Key indicators: ISSN 2352-3018; H-index 101; SJR 4.757; Q1 quartile.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (101): Exceptionally high — 101 articles have each been cited at least 101 times. This indicates deep, sustained influence in the field.
- SJR (4.757): SCImago Journal Rank weights citations by the prestige of citing journals. A value above 2 indicates the journal's articles are cited by high-prestige venues.
- Quartile (Q1): Ranked Q1 among journals in its subject category — top 25%, the highest tier.
Publishing in The Lancet HIV
As a top-tier journal, this venue is highly selective. Expect rigorous peer review, low acceptance rates, and intense competition. Submit only your strongest, most significant work.
- Scope fit: Confirm your research aligns with Immunology and Microbiology; Medicine. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of The Lancet HIV?
2352-3018.
Who publishes The Lancet HIV?
Elsevier Ltd.
What are The Lancet HIV's metrics?
H-index 101.
Is The Lancet HIV peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Journal Metrics
A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Reimagining HIV service integration
Gifty Marley, Nittaya Phanuphak, Weiming Tang
2026-10 · DOI: 10.1016/s2352-3018(26)00254-7Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Cécile Tremblay, Innocent Valea, Birahim Pierre Ndiaye, Houreratou Barry et al.
2026-10 · DOI: 10.1016/s2352-3018(26)00118-9Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa
Kim Steegen, Jeremy Nel, Erin H Smeijsters, Chijioke N Umunnakwe et al.
2026-10 · DOI: 10.1016/s2352-3018(26)00144-xAdvancing a fixed-dose combination for children with HIV
Sharon Nachman
2026-10 · DOI: 10.1016/s2352-3018(26)00199-2Metabolic dysfunction-associated steatotic liver disease in people living with HIV: a framework for integrated screening and care
Giada Sebastiani, Tzu-Hao Lee, Ahmed Cordie, Felice Cinque et al.
2026-10 · DOI: 10.1016/s2352-3018(26)00172-4100% committed to life
Ed Holt
2026-10 · DOI: 10.1016/s2352-3018(26)00196-7Correction to Lancet HIV 2026; 13: e569–610
2026-10 · DOI: 10.1016/s2352-3018(26)00233-xHungary's LGBTQ+ and HIV communities’ cautious optimism
Ed Holt
2026-10 · DOI: 10.1016/s2352-3018(26)00145-1Early lessons from lenacapavir PrEP roll-out in Zimbabwe
Lungelo Ndhlovu
2026-10 · DOI: 10.1016/s2352-3018(26)00257-2Virological failure and treatment interruption among people with unsuppressed viral load on antiretroviral therapy: a cross-sectional analysis of Population-based HIV Impact Assessment surveys in seven sub-Saharan African countries
Mansoor Farahani, Suzue Saito, Shannon M Farley, Theodore F Smart et al.
2026-10 · DOI: 10.1016/s2352-3018(26)00171-2Using circus skills to tell stories about HIV/AIDS
Peter Ranscombe
2026-10 · DOI: 10.1016/s2352-3018(26)00261-4Epidemiological trends of HIV among individuals aged 15–54 years in South Africa from 2004 to 2025: a population-based, longitudinal cohort study
Elphas Okango, Margot Otto, Khai Hoan Tram, Adrian Dobra et al.
2026-10 · DOI: 10.1016/s2352-3018(26)00180-3Correction to Lancet HIV 2026; 13: e557–68
2026-10 · DOI: 10.1016/s2352-3018(26)00235-3Ebola virus disease outbreaks and HIV control
Marguerite Massinga Loembe, Edlom P Tchadie, Selidji T Agnandji
2026-10 · DOI: 10.1016/s2352-3018(26)00225-0Programmatic effectiveness of tuberculosis preventive treatment for people with HIV in six high-tuberculosis-burden countries (PROTECT): a prospective cohort study and meta-analysis
N Sarita Shah, Fadimatu Mishara, Seth Zissette, Romaine Nephtalie Mesidor et al.
2026-10 · DOI: 10.1016/s2352-3018(26)00140-2Correction to Lancet HIV 2026; 13: e478–89
2026-10 · DOI: 10.1016/s2352-3018(26)00181-5Turkish Government crackdown on HIV and LGBTQ+ groups
The Lancet HIV
2026-10 · DOI: 10.1016/s2352-3018(26)00232-8Differentiated service delivery and self-care in HIV
Anna Grimsrud, Florence Riako Anam, Cheryl Case Johnson, Ingrid T Katz et al.
2026-10 · DOI: 10.1016/s2352-3018(26)00149-9Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial
Anne E M Kamphuis, Nicolas Salvadori, Hilda Angela Mujuru, Mutsawashe Bwakura-Dangarembizi et al.
2026-10 · DOI: 10.1016/s2352-3018(26)00168-2Epidemiology and management of HIV-2
Serge Paul Eholié, Charlotte Charpentier, Zelica Diallo, Oumarou I Wone Adama et al.
2026-10 · DOI: 10.1016/s2352-3018(26)00170-0Reviews
Community Reviews
Version History
October 11, 2026 at 2:49 pm
October 10, 2026